Learn about CIS Display™, a powerful antibody discovery tool
CIS Display™ is a cell-free alternative to traditional phage display methods. It allows the display of our ultra high-diversity libraries, up to 10^14.
What is CIS Display™?
Unlike phage, yeast, or mammalian display, CIS Display™ does not involve a biological system. This means that larger libraries can be mined effectively.
Originally developed by a team at Isogenica including our current Non-Executive Director Dr. Bill Eldridge, CIS Display™ was first designed to interrogate high-diversity peptide libraries. Over time, this was extended very successfully to increasingly complex small format scaffolds such as Centyrins and VHHs.
Why do we use CIS Display™?
- Display Capacity: Because CIS Display™ is completely cell-free, our synthetic library sizes aren’t limited by a transformation step. This means we can not only create huge libraries, but we can mine them effectively too.
- Scalability: Driven by PCR reactions, we can enrich many different panning arms simultaneously, via our HTP automation. This allows us to experiment with a wider set of conditions such as antigen concentrations, epitope masking, or specific elution to give us the best chance of finding the right conditions to drive towards a TPP.
- Big Data: By seamlessly integrating next-generation sequencing (NGS) analysis, we benefit further from the additional diversity of our libraries, allowing enrichment analysis and identification of rare binders – particularly important with more challenging targets such as membrane proteins.
Use Cases
CIS Display™ has been successfully used in many discovery campaigns. Our most recent success story includes the discovery of a Centyrin for our partner Aro Biotherapeutics that is currently included in a Phase 1b clinical trial for Pompe Disease.
Publications
CIS display, a DNA-based in vitro selection technology for therapeutic peptides
CIS display is a DNA-based in vitro display technology that enables the display and selection of peptides and proteins from extremely large libraries…
CIS display: In vitro selection of peptides from libraries of protein–DNA complexes
PNAS published February 23, 2004. 101 (9) 2806-2810
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. DownloadExtending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD